PMC:7195088 / 30909-31117 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T32","span":{"begin":31,"end":33},"obj":"Body_part"},{"id":"T33","span":{"begin":47,"end":55},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"fma_id","subj":"T32","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A33","pred":"fma_id","subj":"T33","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. Open-label RCT (NCT04329650, not yet recruiting). Primary endpoint: ICU admission (follow-up 29 days)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T160","span":{"begin":97,"end":105},"obj":"Disease"}],"attributes":[{"id":"A160","pred":"mondo_id","subj":"T160","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. Open-label RCT (NCT04329650, not yet recruiting). Primary endpoint: ICU admission (follow-up 29 days)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T171","span":{"begin":112,"end":117},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. Open-label RCT (NCT04329650, not yet recruiting). Primary endpoint: ICU admission (follow-up 29 days)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T414","span":{"begin":31,"end":33},"obj":"Chemical"},{"id":"T416","span":{"begin":61,"end":79},"obj":"Chemical"},{"id":"T417","span":{"begin":112,"end":117},"obj":"Chemical"}],"attributes":[{"id":"A414","pred":"chebi_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A415","pred":"chebi_id","subj":"T414","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A416","pred":"chebi_id","subj":"T416","obj":"http://purl.obolibrary.org/obo/CHEBI_6888"},{"id":"A417","pred":"chebi_id","subj":"T417","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. Open-label RCT (NCT04329650, not yet recruiting). Primary endpoint: ICU admission (follow-up 29 days)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T242","span":{"begin":107,"end":156},"obj":"Sentence"},{"id":"T243","span":{"begin":157,"end":208},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. Open-label RCT (NCT04329650, not yet recruiting). Primary endpoint: ICU admission (follow-up 29 days)"}